Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial

Details

Ressource 1Download: serval:BIB_27096E952FE6.P001 (724.47 [Ko])
State: Public
Version: author
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_27096E952FE6
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial
Journal
Journal of Infectious Diseases
Author(s)
Calandra  T., Glauser  M. P., Schellekens  J., Verhoef  J.
ISSN
0022-1899 (Print)
Publication state
Published
Issued date
08/1988
Volume
158
Number
2
Pages
312-9
Language
english
Notes
Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't --- Old month value: Aug
licence nationale
Abstract
In a randomized, double-blind, multicenter trial we compared the efficacy of a preparation of human IgG antibody to Escherichia coli J5 (J5-IVIG) with that of a standard IgG preparation (IVIG) for the treatment of gram-negative septic shock. At study entry, patients received a single intravenous dose of 200 mg/kg of body weight (maximal dose, 12 g) of either J5-IVIG or IVIG. Of the 100 patients randomized, 71 (30 receiving J5-IVIG and 41 receiving IVIG) had a documented gram-negative infection. Mortality from gram-negative septic shock was 50% (15 of 30) in J5-IVIG recipients and 49% (20 of 41) in IVIG recipients. In addition, treatment with J5-IVIG did not reduce the number of systemic complications of shock and did not delay the occurrence of death due to septic shock. Thus we conclude that J5-IVIG was not superior to IVIG in reducing mortality or in reversing gram-negative septic shock.
Keywords
Adolescent Adult Aged Child Clinical Trials Double-Blind Method Escherichia coli/*immunology Female Gram-Negative Bacteria Humans *Immunization, Passive Immunoglobulin G/immunology/*therapeutic use Immunoglobulins, Intravenous Male Middle Aged Prospective Studies Random Allocation Sepsis/complications/therapy Shock, Septic/complications/mortality/*therapy
Pubmed
Web of science
Open Access
Yes
Create date
25/01/2008 14:28
Last modification date
01/10/2019 7:17
Usage data